Company Filing History:
1 out of 26 
1 out of 2 Years Active: 2025
Title: Marc Peter Ciucci: Innovator in Therapeutic Monoclonal Antibodies
Introduction
Marc Peter Ciucci is a notable inventor based in Cranbury, NJ (US). He has made significant contributions to the field of therapeutic monoclonal antibodies, particularly with his innovative work on anti-FXI/FXIa antibodies. His research focuses on developing solutions for coagulation and thromboembolism-related disorders.
Latest Patents
Marc Peter Ciucci holds a patent for an "Anti-FXI/FXIa antibody and use thereof." This invention relates to therapeutic monoclonal antibodies and provides an anti-FXI/FXIa antibody or an antigen-binding fragment. The patent includes nucleic acid molecules encoding the antibody and methods for preparing it. The described antibody exhibits specificity and high affinity to FXI/FXIa, effectively inhibiting its activity. Furthermore, the invention offers a pharmaceutical composition comprising the antibody, which can be used in the prevention and treatment of diseases related to coagulation or thromboembolism.
Career Highlights
Throughout his career, Marc has worked with prominent companies in the biopharmaceutical sector. He has been associated with Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. and Klus Pharma Inc. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.
Collaborations
Marc has collaborated with notable professionals in his field, including Haijun Tian and Dengnian Liu. These collaborations have further enhanced his research and development efforts in monoclonal antibody therapies.
Conclusion
Marc Peter Ciucci is a distinguished inventor whose work in therapeutic monoclonal antibodies has the potential to significantly impact the treatment of coagulation disorders. His innovative patent and collaborations reflect his commitment to advancing medical science.